Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

Rhea-AI Summary

Insmed (Nasdaq: INSM) will release its second-quarter 2026 financial results on Thursday, August 6, 2026. Management will host a conference call for investors at 8:00 a.m. ET that day to discuss the results and provide a business update, with live access by phone and webcast.

Participants can join via U.S. dial-in (888) 210-2654 or international (646) 960-0278 using access code 7862189, or listen through the company website. A telephone replay will be available until August 13, 2026, and the webcast will be archived for 90 days in Insmed’s Investor Relations section.

News Market Reaction – INSM

+0.72%

+0.72% Session close to close

In the Jul 23 session, INSM gained 0.72%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

INSM's effective S-3ASR shelf runs through May 15, 2029. The scheduled results call provides the nex...

Analysis

INSM's effective S-3ASR shelf runs through May 15, 2029. The scheduled results call provides the next formal update; recent Net Selling insider activity remains a separate risk factor to monitor.

Key Figures

Reporting Period: second-quarter 2026 Results Date: Thursday, August 6, 2026 Conference Call Time: 8:00 a.m. ET +2 more

5 metrics

Reporting Period second-quarter 2026 Financial results release

Results Date Thursday, August 6, 2026 Scheduled financial results release

Conference Call Time 8:00 a.m. ET August 6, 2026 investor call

Replay Availability through August 13, 2026 Telephone replay of the conference call

Webcast Archive 90 days Investor Relations website archive

Previous Conferences,earnings date Reports

5 past events · Latest: Apr 23 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 23	earnings date notice	Neutral	-0.5%	Scheduled first-quarter 2026 results and an 8:00 a.m. ET conference call
Feb 05	earnings date notice	Neutral	-0.9%	Scheduled fourth-quarter and full-year 2025 results and investor conference call
Oct 15	earnings date notice	Neutral	+1.3%	Scheduled third-quarter 2025 results and an investor conference call
Jul 24	earnings date notice	Neutral	+0.1%	Scheduled second-quarter 2025 results and an 8:00 a.m. ET call
Apr 23	earnings date notice	Neutral	-0.6%	Scheduled first-quarter 2025 results and an investor conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The five tag-matched earnings-date announcements produced mixed 24-hour reactions, with three negative moves and two positive moves.

Key Terms

gene therapy, rna end-joining

2 terms

gene therapy medical

"including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

rna end-joining technical

"AI-driven protein engineering, RNA end-joining, and synthetic rescue"

RNA end-joining is a biochemical process in which two broken or separate RNA molecules are enzymatically linked together to form a continuous strand, similar to taping the ends of two ripped pages to make one sheet. It underlies natural RNA repair and laboratory techniques used in making or analyzing RNA-based drugs, gene therapies, and diagnostic tests, so it matters to investors because it affects how RNA products are made, measured, and how well they may work.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.

Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live on the Company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion through August 13, 2026, by dialing (800) 770-2030 (U.S.) and (609) 800-9909 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases— as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2026-financial-results-conference-call-on-thursday-august-6-2026-302832449.html

SOURCE Insmed Incorporated

FAQ

When will Insmed (INSM) report its Q2 2026 earnings results?

Insmed will release its second-quarter 2026 financial results on Thursday, August 6, 2026. According to Insmed, management will discuss the results and provide a business update on a conference call scheduled for 8:00 a.m. Eastern Time that same day.

What time is Insmed's Q2 2026 earnings conference call on August 6, 2026?

Insmed’s Q2 2026 earnings conference call is scheduled for 8:00 a.m. ET on August 6, 2026. According to Insmed, the call will cover quarterly financial results and a business update for investors and interested parties.

How can investors join the Insmed (INSM) Q2 2026 earnings call?

Investors can join the Insmed Q2 2026 call by dialing (888) 210-2654 in the U.S. or (646) 960-0278 internationally, using access code 7862189. According to Insmed, the call will also stream live via webcast on the company’s website.

Will a replay be available for Insmed's August 6, 2026 Q2 2026 earnings call?

Yes, a replay of Insmed’s August 6, 2026 call will be available until August 13, 2026. According to Insmed, investors can dial (800) 770-2030 in the U.S. or (609) 800-9909 internationally with access code 7862189, or access an archived webcast for 90 days.

Where can I listen to the Insmed (INSM) Q2 2026 earnings webcast and archive?

The Insmed Q2 2026 earnings webcast will be available live on www.insmed.com. According to Insmed, an archived version will remain under the Investor Relations section of the website for 90 days following the August 6, 2026 conference call.

What does Insmed (INSM) do as a biopharmaceutical company?

Insmed is a global biopharmaceutical company focused on first- and best-in-class therapies for serious diseases. According to Insmed, it has approved and late-stage investigational medicines in Respiratory, Immunology & Inflammation, and Neuro & Other Rare, supported by advanced technologies such as gene therapy and AI-driven protein engineering.